Monitor regulatory progress in Canada, Australia, and New Zealand; no near-term revenue catalyst as commercialization is not expected until 2028. The deal modestly expands Evolus's international platform but does not change the near-term financial outlook.
Price Chart
Executive Summary
Evolus expanded its partnership with Symatese to exclusively commercialize the Estyme injectable HA gel portfolio in Canada, Australia, and New Zealand. The amendment requires upfront payments of 920,000 and up to 1.38 million in milestone payments, with commercialization expected in 2028 subject to regulatory approvals. This is a strategic but non-transformative territorial expansion with no near-term revenue impact.
Key Financial Metrics
Key Facts
- Upfront signing payment of 920,000 and up to 1.38 million in regulatory milestone payments
- Exclusive rights to commercialize Estyme (HA gel) in Canada, Australia, and New Zealand
- Initial term of 15 years from first regulatory approval, auto-renewing for five-year terms
- Commercialization expected in 2028, subject to regulatory approvals
- Combined neurotoxin and dermal filler TAM in these territories is approximately $500 million annually
- Symatese remains responsible for development, manufacturing, and regulatory activities
Financial Impact
Upfront payment of 920,000 plus up to 1.38 million in milestones; mid-single digit royalty on net sales; expected to be accretive to international gross margins
Risk Factors
- Regulatory approval delays or failures in any of the three territories
- Competition from established dermal filler brands (e.g., Allergan, Galderma)
- Consumer discretionary spending sensitivity in aesthetic markets
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001570562-26-000083 |
| Document: a8k8426ex991.htm | 0001570562-26-000083 |
| Document: 0001570562-26-000083-index-headers.html | 0001570562-26-000083 |
| Document: 0001570562-26-000083-index.html | 0001570562-26-000083 |
| Document: 0001570562-26-000083.txt | 0001570562-26-000083 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 13, 2026 10w ago | Institutional Cluster | $8.02 $8.16 | ▲ +1.68% | ▲ +1.88% | $7.17 (−10.60%) |
Aug 4, 2026 11w ago | 8-K | $6.12 $6.18 | ▲ +0.98% | ▲ +1.18% | $7.17 (+17.16%) |
Jul 8, 2026 15w ago | 8-K | $6.79 $6.85 | ▲ +0.88% | ▲ +0.04% | $7.17 (+5.60%) |
Jun 15, 2026 19w ago | EFFECT | $6.75 $6.63 | ▼ −1.78% | ▼ −1.18% | $7.17 (+6.22%) |
Jun 5, 2026 20w ago | S-3 | $6.68 $6.70 | ▲ +0.30% | ▲ +0.59% | $7.17 (+7.34%) |
Apr 29, 2026 25w ago | DEFA14A | $5.18 $5.39 | ▲ +4.05% | ▲ +3.03% | $7.17 (+38.42%) |
Mar 17, 2026 32w ago | Insider Cluster | $4.91 $4.83 | ▲ +1.63% | ▲ +0.23% | $7.17 (−46.03%) |
Mar 17, 2026 32w ago | Insider Cluster | $4.91 $4.83 | ▲ +1.63% | ▲ +0.23% | $7.17 (−46.03%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers